Medtronic Trial for AFib System Achieves Endpoints
By Ben Glickman
Medtronic said its combined system for use during treatment of atrial fibrillation reached its safety and efficacy endpoints in a trial.
The medical-device company said that the Affera Mapping and Ablation System with Sphere-9 Catheter, an ablation and mapping system, showed higher freedom from AFib compared with the control arm of the trial and had a comparable safety profile.
The Affera system with Sphere-9 catheter was specifically being evaluated in cases of persistent AFib, which makes up 30% to 50% of patients.
The company said it had recently filed for approval of the combined system in the U.S.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
May 17, 2024 17:03 ET (21:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
GE Aerospace Stock Has Skyrocketed 86%. Is It a Buy?
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates